Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Market price (% of par)
-
82.81%
-
Total 13F principal
-
$500,126,237
-
Principal change
-
-$232,417,065
-
Total reported market value
-
$418,687,950
-
Number of holders
-
44
-
Value change
-
-$191,611,306
-
Number of buys
-
10
-
Number of sells
-
30
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q1 2020
As of 31 Mar 2020 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 had 44 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $500,126,237 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Allianz Asset Management GmbH, CANYON CAPITAL ADVISORS LLC, STEELHEAD PARTNERS LLC, UBS ASSET MANAGEMENT AMERICAS INC, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, Davidson Kempner Capital Management LP, WOLVERINE ASSET MANAGEMENT LLC, STATE STREET CORP, and OAKTREE CAPITAL MANAGEMENT LP.
This table shows 44 bond principal holders of the security as of 31 Mar 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par) |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.